| Summary: | 碩士 === 臺北醫學大學 === 藥理學研究所 === 94 === Quercetin-3,5,7,3',4'-O-pentamethylether (QPME) inhibited activities of PDE1~4, with IC50 values < 10 M. The PDE4H/PDE4L ratio of QPME is about 11, equal to that of AWD 12-281 which is in clinical trial phase II. QPME whether possesses anti-asthmatic effect is the aim of this investigation.
In vivo, female BALB/c mice were sensitized by an intraperitoneal injection of ovalbumin (OVA), then challenged via the airway by ultrasonic nebulization of 1% OVA two periods (secondary challenge). After secondary challenge, the airway hyperresponsiveness (AHR) was measured in unrestrained animals, nebulized with methacholine (MCh, 6.25~50 mg/ml), by barometric plethysmography using a whole-body plethysmograph. In the present results, QPME (10~100 mol/kg, i.p.) dose-dependently attenuated the enhanced pause (Penh) value induced by MCh (25~50 mg/ml). Furthermore, QPME (100 mol/kg, i.p.) also significantly inhibited MCh (25 mg/ml)-induced Penh value. QPME (10-100 mol/kg, i.p.) also significantly inhibited total inflammatory cells, macrophages, neutrophils , lymphocytes, and eosinophils in BALF after determination of Penh values. It also significantly attenuated the release of IL-2, IL-4, IL-5, IFN-γ, and TNF-α, with some exceptions that QPME at the least dose did not suppress releases of total inflammatory cells, macrophages, IL-5, and IFN-γ.
In vitro, QPME (30~100 M) significantly relaxed baseline tension and inhibited cumulative OVA (10~100 μg/ml)-induced contractions in isolated sensitized guinea pig trachealis.
According to the Lineweaver-Burk analysis, QPME (3~30 M) competitively inhibited PDE1, PDE2, PDE3, and PDE4 activities. The Ki values were 0.89, 1.07, 0.53, and 0.52 M which did not differ each other. Owing to QPME did not selectively inhibited PDE1-4, and resulted increase of intracellular cAMP, it may possess anti-inflammatory and anti-asthmatic effects.
|
|---|
